正常细胞周期调控机制的丧失是肿瘤的特征 ,这为发展靶向关卡调控为基础的新的肿瘤治疗策略提供了许多机会。这些策略包括对细胞周期关卡阻止的诱导 ,阻滞肿瘤细胞在治疗剂敏感的细胞周期阶段 ,和针对特异性细胞周期调控因子的靶治疗。细胞周期和细胞周期关卡因子为新型抗癌药物提供了丰富的靶位 ,这些药物主要是周期素依赖性激酶抑制剂和关卡取消剂 ,它们可以增强DNA损伤剂的抗肿瘤活性。 The loss of normal cell cycle regulatory mechanisms is characteristic of tumors, which provides many opportunities for the development of new tumor treatment strategies based on targeted checkpoint regulation. These strategies include the induction of cell cycle checkpoints, the arrest of tumor cells in therapeutically sensitive cell cycle phases, and the targeting of specific cell cycle regulators. The cell cycle and cell cycle checkpoint factors provide a wealth of targets for novel anticancer drugs. These drugs are mainly cyclin-dependent kinase inhibitors and checkpoint removers, which can enhance the antitumor activity of DNA damaging agents.